Exagamglogene Autotemcel (Casgevy)

Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform nonbinding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec. This review assesses exagamglogene autotemcel (Casgevy), Cell suspension in patient-specific vials, 4 to 13 × 106 cells/mL, for IV infusion. Indication: For the treatment of patients 12 years of age and older with sickle cell disease with recurrent vaso-occlusive crises.